CD8α antibody-mediated depletion showed a trend toward some impact on tumor antigen uptake by CD103+ DCs, which could be an indirect effect of removing CD8α+ DCs by the antibody, but transient intratumoral depletion of T cells (Besançon et al., 2017) in the first few days of treatment did not alter long-term survival in response to 1X AIP therapy (Figure S3I). This evidence concerns the gene ITGAE and neoplasm.